In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $7.67 in the prior trading day, Capricor Therapeutics Inc (NASDAQ: CAPR) closed at $7.74, up 0.91%. In other words, the price has increased by $0.91 from its previous closing price. On the day, 0.72 million shares were traded. CAPR stock price reached its highest trading level at $7.825 during the session, while it also had its lowest trading level at $7.52.
Ratios:
Our goal is to gain a better understanding of CAPR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.55 and its Current Ratio is at 6.55. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Alliance Global Partners on June 30, 2025, initiated with a Buy rating and assigned the stock a target price of $20.
On June 26, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $21.
On May 20, 2025, Roth Capital started tracking the stock assigning a Buy rating and target price of $31.Roth Capital initiated its Buy rating on May 20, 2025, with a $31 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 20 ’24 when Nippon Shinyaku Co Ltd bought 2,798,507 shares for $5.36 per share. The transaction valued at 14,999,998 led to the insider holds 7,090,351 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CAPR now has a Market Capitalization of 353778368 and an Enterprise Value of 210250624. For the stock, the TTM Price-to-Sale (P/S) ratio is 20.38 while its Price-to-Book (P/B) ratio in mrq is 2.77. Its current Enterprise Value per Revenue stands at 12.109 whereas that against EBITDA is -3.769.
Stock Price History:
The Beta on a monthly basis for CAPR is 0.76, which has changed by 0.9948454 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, CAPR has reached a high of $23.40, while it has fallen to a 52-week low of $3.52. The 50-Day Moving Average of the stock is -19.66%, while the 200-Day Moving Average is calculated to be -40.41%.
Shares Statistics:
The stock has traded on average 3.11M shares per day over the past 3-months and 1988230 shares per day over the last 10 days, according to various share statistics. A total of 45.68M shares are outstanding, with a floating share count of 40.15M. Insiders hold about 12.16% of the company’s shares, while institutions hold 40.71% stake in the company. Shares short for CAPR as of 1752537600 were 9801806 with a Short Ratio of 3.16, compared to 1749772800 on 10214148. Therefore, it implies a Short% of Shares Outstanding of 9801806 and a Short% of Float of 24.4.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Capricor Therapeutics Inc (CAPR) is the result of assessments by 8.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.4 and low estimates of -$0.54.
Analysts are recommending an EPS of between -$1.65 and -$2.07 for the fiscal current year, implying an average EPS of -$1.9. EPS for the following year is $0.69, with 8.0 analysts recommending between $3.5 and -$2.49.
